Standout Papers
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial (2023)
- Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023)
- Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025)
Immediate Impact
55 standout
Citing Papers
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
2025 Standout
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
2025 Standout
Works of K. Lucas being referenced
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
2023 Standout
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2023 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| K. Lucas | 285 | 251 | 88 | 12 | 459 | |
| Bankim A. Bhatt | 157 | 129 | 147 | 14 | 574 | |
| Hong Liu | 263 | 95 | 67 | 21 | 415 | |
| Ching Fai Kwok | 111 | 176 | 125 | 21 | 491 | |
| Ronald G. Tompkins | 185 | 13 | 91 | 10 | 500 | |
| Kahui Park | 191 | 252 | 70 | 11 | 539 | |
| A. M. Dall’Omo | 133 | 149 | 73 | 12 | 484 | |
| Heba M. Ibrahim | 98 | 334 | 23 | 9 | 517 | |
| Bjoern M. Thobe | 127 | 24 | 90 | 13 | 459 | |
| Heather J. Saunders | 32 | 106 | 169 | 15 | 532 | |
| R Casamitjana | 238 | 94 | 49 | 12 | 420 |
All Works
Loading papers...